Interview with the CEO: Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)

Healthcare >> CEO Interviews >> October 6, 2023

Robert Barrow is the Chief Executive Officer and Board Director of Mind Medicine (MindMed) Inc. Mr. Barrow is an accomplished pharmaceutical executive and clinical pharmacologist with over a decade of experience leading drug development programs in a variety of disease areas. After joining MindMed as Chief Development Officer in January 2021, he was named CEO in June 2021. Mr. Barrow previously served as Director of Drug Development & Discovery at Usona Institute, where he oversaw preclinical, clinical and regulatory development efforts for all of Usona’s development programs. Prior to joining Usona, Mr. Barrow served as Chief Operating Officer of Olatec Therapeutics, LLC, a private, clinical-stage biopharmaceutical company, where he oversaw the execution of numerous early- and late-stage clinical trials in the fields of analgesics, rheumatology, immunology and cardiovascular disease. In addition, he has been responsible for the design and execution of preclinical research programs for new molecular entity drugs in brain health disorders. Mr. Barrow has also served as both a technical and business adviser to numerous pharmaceutical organizations ranging from startups to Fortune 500 companies. Profile

Word count: 3,430

TWST: MindMed is the first publicly traded psychedelics company in the world. How did you get to this point?

Mr. Barrow: Yes, it’s been an

Join for free to read a longer excerpt or purchase this article

Interview with the CEO: Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)

Top Company Interviews

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS

Interview with the CEO: Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)

Top Company Interviews

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS